Company opts not to advance VX-993 into pivotal development after Phase II data show no statistically significant benefit ...

"Spine BioPharma’s trial of SB-01 fails to meet primary endpoint" was originally created and published by Clinical Trials ...

NEW YORK, NY, USA I August 01, 2025 I Spine BioPharma, Inc. announced today the Phase 3 MODEL trial (MOderate – Severe Degenerative Disc Disease Evaluation of ...

Diagnostic indicators are identified for confirming chronic neuropathic ocular pain (NOP) for patients experiencing chronic dry eye (DE) after laser-assisted in situ keratomileusis (LASIK).

Diagnostic indicators are identified for confirming chronic neuropathic ocular pain for patients experiencing chronic dry eye after LASIK.

In a study published in the August issue of the American Journal of Ophthalmology, diagnostic indicators are identified for confirming chronic neuropathic ocular pain (NOP) for patients ...

Detailed price information for Tonix Pharm Holdings (TNXP-Q) from The Globe and Mail including charting and trades.

Pain intensity and disability were assessed using scales like the Numerical Pain Rating Scale and Oswestry Disability Index, respectively, along with other measures, and the certainty of evidence ...

Results demonstrated a more than 80% improvement in Oswestry Disability Index (ODI) scores and greater than 70% reduction in Numeric Pain Rating Scale scores after HYDRAFIL treatment, with ...

Vertex Pharmaceuticals is diversifying from its cystic fibrosis dominance into pain and other markets. Check out our recommendation for VRTX stock.